

Statement re. HSE Prosecution

RNS Number : 1680U

Novacyt S.A.

21 January 2025

NOVACYT

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Statement re. Health and Safety Executive Prosecution

Paris, France, and Eastleigh and Manchester, UK - 21 January 2025 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that, following an investigation by the Health and Safety Executive ("HSE"), Lab 21 Healthcare Ltd ("Lab 21"), a non-trading subsidiary of Novacyt, has been charged with health and safety offences relating to a facility it previously operated.

The charges relate to Lab 21's site based at Axminster, Devon and relate to the use of biological agents at the site. The lease for the site was taken over by Lab 21 from Omega Diagnostics Ltd ("Omega"), as part of the acquisition by Lab 21 of Omega's Infectious Diseases business announced on 28 June 2018. The operations that are subject to the charges no longer form any part of the Company's ongoing business.

An initial Magistrates' Court hearing has been set for 18 March 2025.

The Company will make a further announcement following the outcome of the case.

Contacts

Novacyt SA

<https://novacyt.com/investors>

Lyn Rees, Chief Executive Officer

Via Walbrook PR

Steve Gibson, Chief Financial Officer

SP Angel Corporate Finance LLP (Nominated Adviser and Broker) +44 (0)20 3470 0470

Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)

Deutsche Numis (Joint Broker) +44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Michael Palser

Allegra Finance (French Listing Sponsor) +33 (1) 42 22 10 10 r.durgetto@allegrafinance.com /
Rémi Durgetto / Yannick Petit y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR) +44 (0)20 7933 8780 or novacyt@walbrookpr.com
Paul McManus / Lianne Applegarth +44 (0)7980 541 893 / +44 (0)7584 391 303
Phillip Marriage / Alice Woodings +44 (0)7867 984 082 / +44 (0)7407 804 654

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical

Broad portfolio of human clinical *in vitro* diagnostic products, workflows and services focused on three therapeutic areas:

- Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
- Precision Medicine: DPYD genotyping assay
- Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation

Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

- Ranger® Technology: automated DNA sample preparation and target enrichment technology
 - genesig q16 and q32 real-time quantitative PCR (qPCR) instruments
-

Research Use Only

Range of services for the life sciences industry:

- Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
- Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Le Vésinet in France with offices in the UK (in Eastleigh and Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

STRUARVRVUAUAR